291 related articles for article (PubMed ID: 25588379)
1. Integrated PK-PD and agent-based modeling in oncology.
Wang Z; Butner JD; Cristini V; Deisboeck TS
J Pharmacokinet Pharmacodyn; 2015 Apr; 42(2):179-89. PubMed ID: 25588379
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology.
Garralda E; Dienstmann R; Tabernero J
Am Soc Clin Oncol Educ Book; 2017; 37():210-215. PubMed ID: 28561730
[TBL] [Abstract][Full Text] [Related]
3. Array of translational systems pharmacodynamic models of anti-cancer drugs.
Ait-Oudhia S; Mager DE
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):549-565. PubMed ID: 27771815
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic.
Zhou Q; Gallo JM
AAPS J; 2011 Mar; 13(1):111-20. PubMed ID: 21246315
[TBL] [Abstract][Full Text] [Related]
6. Translational pharmacokinetic/pharmacodynamic analysis in cancer pharmacology: a tool to maximize the value of antitumor efficacy from tumor bearing mice.
Wong H; Gould SE
Drug Discov Today Technol; 2016; 21-22():51-56. PubMed ID: 27978988
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic guided trial design in oncology.
van Kesteren Ch; Mathôt RA; Beijnen JH; Schellens JH
Invest New Drugs; 2003 May; 21(2):225-41. PubMed ID: 12889741
[TBL] [Abstract][Full Text] [Related]
8. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
Yamazaki S; Spilker ME; Vicini P
Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
[TBL] [Abstract][Full Text] [Related]
9. Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.
Buil-Bruna N; López-Picazo JM; Martín-Algarra S; Trocóniz IF
Oncologist; 2016 Feb; 21(2):220-32. PubMed ID: 26668254
[TBL] [Abstract][Full Text] [Related]
10. Mathematical modeling and computational prediction of cancer drug resistance.
Sun X; Hu B
Brief Bioinform; 2018 Nov; 19(6):1382-1399. PubMed ID: 28981626
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients.
Avramis VI; Spence SA
J Pediatr Hematol Oncol; 2007 Apr; 29(4):239-47. PubMed ID: 17414566
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
14. Translational approach from preclinical to clinical: comparison of dose finding methods of a new Bcl2 inhibitor using PK-PD modeling and interspecies extrapolation.
Pierrillas PB; Henin E; Ogier J; Amiel M; Kraus-Berthier L; Chenel M; Bouzom F; Tod M
Invest New Drugs; 2020 Dec; 38(6):1796-1806. PubMed ID: 32451663
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic and pharmacodynamic modeling in cancer drug development: status, potential and gaps.
Block M
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):743-56. PubMed ID: 25940026
[TBL] [Abstract][Full Text] [Related]
16. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
18. Current mathematical models for cancer drug discovery.
Carrara L; Lavezzi SM; Borella E; De Nicolao G; Magni P; Poggesi I
Expert Opin Drug Discov; 2017 Aug; 12(8):785-799. PubMed ID: 28595492
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Li J; Jameson MB; Baguley BC; Pili R; Baker SD
Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
[TBL] [Abstract][Full Text] [Related]
20. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
